On March 27, 2024, the PTAB summarily denied Seagen’s February 14, 2024 request for Director Review of the PTAB’s January 16, 2024 Final Written Decision (“FWD”) in PGR2021-00030 related to Adcetris^® (brentuximab vedotin).  In the FWD, the PTAB held that the antibody-drug conjugate claims in U.S. Patent No. 10,808,039 were unpatentable.  See Seagen Requests Director Review of Unpatentability Decision in Adcetris® Patent PGR; see also PTAB Issues Final Written Decision Finding Seagen’s Adcetris® Patent Claims Unpatentable.

_____________________________________________________

The authors would like to thank April Breyer Menon for her contributions to this article.